Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Current Assets (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Current Assets for 5 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 38.08% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 38.08% year-over-year, with the annual reading at $1.0 billion for FY2025, 38.08% up from the prior year.
  • Current Assets hit $1.0 billion in Q4 2025 for Krystal Biotech, up from $925.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.0 billion in Q4 2025 to a low of $345.8 million in Q3 2021.
  • Historically, Current Assets has averaged $576.0 million across 5 years, with a median of $533.1 million in 2023.
  • Biggest five-year swings in Current Assets: decreased 18.85% in 2023 and later surged 69.44% in 2024.
  • Year by year, Current Assets stood at $442.3 million in 2021, then dropped by 13.22% to $383.8 million in 2022, then soared by 53.19% to $587.9 million in 2023, then rose by 26.22% to $742.0 million in 2024, then skyrocketed by 38.08% to $1.0 billion in 2025.
  • Business Quant data shows Current Assets for KRYS at $1.0 billion in Q4 2025, $925.6 million in Q3 2025, and $841.3 million in Q2 2025.